The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 118-123 , 19 December 2005

Centrally active nonhormonal hot flash therapies

  • Charles L. Loprinzi, MD

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Charles L. Loprinzi, MD, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, Minnesota 55905.
    • ,
  • Vered Stearns, MD

      Affiliations

    • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    • ,
  • Debra Barton, PhD, RN

      Affiliations

    • Mayo Clinic College of Medicine, Rochester, Minnesota, USA

References 

  1. Lebherz TB , French L . Nonhormonal treatment of the menopause syndrome . Obstet Gynecol . 1969;33:795–799
  2. Bergmans MG , Merkus JM , Corbey RS , Schellekens LA , Ubachs JM . Effect of Bellergal Retard on climacteric complaints (a double-blind, placebo-controlled study) . Maturitas . 1987;9:227–234
  3. Goldberg RM , Loprinzi CL , O’Fallon JR , et al.   Transdermal clonidine for ameliorating tamoxifen-induced hot flashes . J Clin Oncol . 1994;12:155–158
  4. Pandya KJ , Raubertas RF , Flynn PJ , et al.   Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes (a University of Rochester Cancer Center Community Clinical Oncology Program study) . Ann Intern Med . 2000;132:788–793
  5. Hammond MG , Hatley L , Talbert LM . A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes . J Clin Endocrinol Metab . 1984;58:1158–1160
  6. Loprinzi CL , Kugler JW , Sloan JA , et al.   Venlafaxine in management of hot flashes in survivors of breast cancer (a randomised controlled trial) . Lancet . 2000;356:2059–2063
  7. Evans ML , Pritts E , Vittinghoff E , McClish K , Morgan KS , Jaffe RB . Management of postmenopausal hot flushes with venlafaxine hydrochloride (a randomized, controlled trial) . Obstet Gynecol . 2005;105:161–166
  8. Stearns V , Beebe KL , Iyengar M , Dube E . Paroxetine controlled release in the treatment of menopausal hot flashes (a randomized controlled trial) . JAMA . 2003;289:2827–2834
  9. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol. In press.
  10. Loprinzi CL , Sloan JA , Perez EA , et al.   Phase III evaluation of fluoxetine for treatment of hot flashes . J Clin Oncol . 2002;20:1578–1583
  11. Kimmick GG , Lovato J , McQuellon R , Robinson E , Muss H . Randomized, placebo-controlled study of sertraline (Zoloft™) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen . [abstract] Proc Am Soc Clin Oncol . 2001;20:1585a
  12. Suvanto-Luukkonen E , Koivunen R , Sundstrom H , et al.   Citalopram and fluoxetine in the treatment of postmenopausal symptoms (a prospective, randomized, 9-month, placebo-controlled, double-blind study) . Menopause . 2005;12:18–26
  13. Guttuso T , Kurlan R , McDermott MP , Kieburtz K . Gabapentin’s effects on hot flashes in postmenopausal women (a randomized controlled trial) . Obstet Gynecol . 2003;101:337–345
  14. Pandya KJ , Roscoe J , Pajon E , et al.   A preliminary report of a double blind placebo controlled trial of gabapentin for control of hot flashes in women with breast cancer (a University of Rochester Cancer Center CCOP study) . [abstract] Proc Am Soc Clin Oncol . 2004;23:8015
  15. Shanafelt TD , Barton DL , Adjei AA , Loprinzi CL . Pathophysiology and treatment of hot flashes . Mayo Clin Proc . 2002;77:1207–1218
  16. Schindler AE , Muller D , Keller E , Goser R , Runkel F . Studies with clonidine (Dixarit) in menopausal women . Arch Gynecol . 1979;227:341–347
  17. Clayden JR , Bell JW , Pollard P . Menopausal flushing (double blind trial of non-hormonal medication) . BMJ . 1974;1:409–412
  18. Laufer LR , Erlick Y , Meldrum DR , Judd HL . Effect of clonidine on hot flashes in postmenopausal women . Obstet Gynecol . 1982;60:583–589
  19. Schmitt H . The pharmacology of clonidine and related products . Handb Exp Pharmacol . 1977;39:299–396
  20. Freedman RR , Disnay R . Clonidine raises the sweating threshold in symptomatic but not in asymptomatic postmenopausal women . Fertil Steril . 2000;74:20–23
  21. Loprinzi CL , Goldberg RM , O’Fallon JR , et al.   Transdermal clonidine for ameliorating postorchiectomy hot flashes . J Urol . 1993;151:634–636
  22. Nesheim BI , Saetre T . Reduction of menopausal hot flashes by methyldopa (a double-blind crossover trial) . Eur J Clin Pharmacol . 1981;20:413–416
  23. Loprinzi CL , Pisansky TM , Fonseca R , et al.   Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors . J Clin Oncol . 1998;16:2377–2381
  24. Stearns V , Isaacs C , Rowland J , et al.   A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors . Ann Oncol . 2000;11:17–22
  25. Barton D , La Vasseur B , Loprinzi C , Novotny P , Wilwerding MB , Sloan J . Venlafaxine for the control of hot flashes (results of a longitudinal continuation study) . Oncol Nurs Forum . 2002;29:33–40
  26. Kalogeropoulos S , Kampas N , Petrogiannopoulos C , et al.   Long-term management of menopausal hot flushes with venlafaxine . [abstract] Gynecol Endocrinol . 2004;18(suppl 1):OP95a
  27. Perez DG , Loprinzi CL , Barton DL , et al.   Pilot evaluation of mirtazapine for the treatment of hot flashes . J Support Oncol . 2004;2:50–56
  28. Barton DL , Loprinzi CL , Novotny P , et al.   Pilot evaluation of citalopram for the relief of hot flashes . J Support Oncol . 2003;1:11–21
  29. Goetz MP , Loprinzi CL . A hot flash on tamoxifen metabolism . J Natl Cancer Inst . 2003;95:1734–1735
  30. Stearns V , Johnson MD , Rae JM , et al.   Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine . J Natl Cancer Inst . 2003;95:1758–1764
  31. Jin F , Desta Z , Stearns V , et al.   Association between CYP2D6 genotype, antidepressants, and tamoxifen metabolism during adjuvant breast cancer treatment . J Natl Cancer Inst . 2005;97:30–39
  32. Goetz MP , Rae JM , Suman VJ , et al.   Pharmacogenomic determinants of outcome with tamoxifen therapy (findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52) . Breast Cancer Res Treat . 2004;88(suppl 1):S35; Abstract 314a
  33. Loprinzi CL , Flynn PJ , Carpenter LA , et al.   Pilot evaluation of citalopram for the treatment of hot flashes in women with inadequate benefit from venlafaxine . J Palliat Med . 2005;8:924–930
  34. Quella SK , Loprinzi CL , Sloan J , et al.   Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer . J Urol . 1999;162:98–102
  35. Loprinzi CL , Barton DL , Carpenter LA , et al.   Pilot evaluation of paroxetine for treating hot flashes in men . Mayo Clin Proc . 2004;79:1247–1251
  36. Shafgat A , Titzer ML , Sweeney CJ , et al.   A phase II study of venlafaxine for the treatment of hot flashes in men undergoing androgen deprivation for prostate cancer . Proc Am Soc Clin Oncol . 2003;23:762; Abstract 8148
  37. Guttuso TJ . Gabapentin’s effects on hot flashes and hypothermia . Neurology . 2000;54:2161–2163
  38. Thummala AR , Griggs J , Rosenblatt J , et al.   Pilot study using gabapentin on tamoxifen-induced hot flashes in women with breast cancer . Proc Am Soc Clin Oncol . 2002;21: Abstract 1445
  39. Loprinzi L , Barton DL , Sloan JA , et al.   Pilot evaluation of gabapentin for treating hot flashes . Mayo Clin Proc . 2002;77:1159–1163

 The opinions offered at the National Institutes of Health (NIH) State-of-the-Science Conference on Management of Menopause-Related Symptoms and published herein are not necessarily those of the National Institute on Aging (NIA) and the Office of Medical Applications of Research (OMAR) or any of the cosponsoring institutes, offices, or centers of the NIH. Although the NIA and OMAR organized this meeting, this article is not intended as a statement of Federal guidelines or policy.Publication of the online supplement was made possible by funding from the NIA and the National Center for Complementary and Alternative Medicine of the NIH, US Department of Health & Human Services.

PII: S0002-9343(05)00903-4

doi: 10.1016/j.amjmed.2005.09.045

The American Journal of Medicine
Volume 118, Issue 12, Supplement 2 , Pages 118-123 , 19 December 2005

Article Tools